Abstracts Archive - Page 117 of 2607 - ACR Meeting Abstracts

Abstract Number: 1029 • ACR Convergence 2025
Cervical cancer screening rates in Korean women of childbearing age with systemic lupus erythematosus
PIL GYU PARK¹, Jisoo Lee², JIN SU PARK³, Hyunsun Lim³, In-Woon Baek⁴, Min Kyung Chung⁴ and Chan Hee Lee⁵, ¹National Health Insurance Service Ilsan Hospital, Seodaemun-gu, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Ewha Womans University College of Medicine, SEOUL, Republic of Korea, ³National Health Insurance Service Ilsan Hospital, Goyang-si, Republic of Korea, ⁴Ewha Womans University College of Medicine, Seoul, Republic of Korea, ⁵Desert Regional Medical Center, Palm Springs, CA
Background/Purpose: Cervical cancer remains a leading cause of death among women of childbearing age despite the proven efficacy of screening in reducing mortality rates. Women…
Abstract Number: 1490 • ACR Convergence 2025
Vitamin D Deficiency and Its Relationship with Inflammatory Biomarkers in SLE: A Focus on Neutrophil-to-Lymphocyte Ratio
judith hernández-Sánchez¹, Beatriz Tejera Segura², Luis Bausá Gimeno¹, Doryan García Olivas¹, Patricia González Terrats¹, MA Acosta Mérida¹, Diana Botello Corzo¹, Daniel Batista perdomo¹, Sergio Machin González¹, F Javier Nóvoa Medina¹ and Jose Angel Hernandez³, ¹Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las palmas, Spain, ²Hospital Insular de Gran Canaria, Las palmas, Spain, ³Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran CanariaHospital, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organs. Vitamin D levels have been associated with disease activity in…
Abstract Number: 1491 • ACR Convergence 2025
Feasibility of Extrarenal Systemic Lupus Erythematosus Disease Modification in GLADEL 2.0, a Latin American Cohort
julián Barahona-correa¹, Santiago Bernal-Macías², Daniel Fernandez³, Óscar Muñoz², Lucia Hernández⁴, Erika Susana Palacios Santillan⁵, Laura Maurelli⁶, Paula Alba⁷, Veronica Saurit⁸, Lucila Garcia⁹, María Emilia Sattler¹⁰, Maria Constanza Bertolaccini¹¹, Marina Laura Micelli¹², Graciela Gomez¹³, Micaela A. Cosatti¹⁴, Ana Carolina Ralle¹⁵, Joaquín Martinez Serventi¹⁶, Ana Silva¹⁷, ODIRLEI MONTICIELO¹⁸, Ángela Luzia Branco Pinto Duarte¹⁹, Laíssa Cristina Alves Alvino²⁰, Eduardo Borba²¹, Eloisa Bonfa²¹, Edgard dos Reis-Neto²², Iris Guerra Herrera²³, Milena Mimica²⁴, Gustavo Aroca Martínez²⁵, Lorena Gómez Escorcia²⁶, Carlos Alberto Cañas²⁷, Gerardo Quintana-Lopez²⁸, Carlos Toro-Gutierrez²⁹, José Maximiliano Martínez Pérez³⁰, Reyna Elizabeth Sánchez-Briones³¹, Mario Pérez Cristóbal³², Eduardo Martin-Nares³³, Yaneli Juarez-Vicuña³⁴, Ignacio García-Valladares³⁵, Rodrigo Ortiz Hernández³⁶, Jorge Antonio Esquivel Valerio³⁷, Maria Isabel Acosta³⁸, Astrid Paats³⁹, Jorge Cieza Calderón⁴⁰, Manuel Ugarte-Gil⁴¹, Armando Calvo⁴², Rodamin Ambiorix Alvarez Santana⁴³, Analía Cánepa⁴⁴, Carina Pizzarossa⁴⁴, Federico Zazzetti⁴⁵, Ashley Orillion⁴⁶ and Cristina Drenkard⁴⁷, ¹Colombian Association of Rheumatology (ASOREUMA), Bogotá, Colombia; Hospital Universitario San Ignacio, Bogotá, Colombia, Bogotá, Colombia, ²Hospital Universitario San Ignacio, Bogotá, Colombia, Bogotá, Colombia, ³Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia; Departamento de Medicina Interna, Unidad de Reumatología, Hospital Universitario San Ignacio, Bogotá, Colombia, BOGOTA, Colombia, ⁴Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, ⁵Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁶Hospital Italiano de Córdoba, Córdoba, Argentina, Córdoba, Argentina, ⁷Hospital Córdoba y Sanatorio Allende, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina, Cordoba, Argentina, ⁸Hospital Privado Universitario de Cordoba, Córdoba, Argentina, Córdoba, Argentina, ⁹Hospital San Martin de La Plata, La Plata, Argentina, La Plata, Argentina, ¹⁰Sanatorio Británico, Rosario, Argentina, Rosario, Argentina, ¹¹Hospital Ángel C. Padilla, Tucumán, Argentina, Tucumán, Argentina, ¹²Hospital J.M Ramos Mejía, Buenos Aires, Argentina, Buenos Aires, ¹³Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁴CEMIC Centro de Educación Médica e Investigaciones Clínicas ‘‘Norberto Quirno,’’ Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁵Hospital Señor del Milagro Salta, Salta, Argentina, Salta, Argentina, ¹⁶Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁷Hospital das Clinicas da Universidade Federal de Goias, Goiania, Brazil, Goiania, Brazil, ¹⁸Hospital de Clínicas de Porto Alegre, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil, PORTO ALEGRE, Rio Grande do Sul, Brazil, ¹⁹Universidad Federal de Pernambuco, Recife, Brazil, Recife, Brazil, ²⁰Hospital Universitário Pedro Ernesto - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio de Janeiro, Brazil, ²¹Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ²²Escola Paulista de Medicina / Universidade federal de São Paulo (EPM / Unifesp), São Paulo, Brazil, São Paulo, Brazil, ²³Hospital del Salvador Santiago de Chile, Santiago, Chile, Santiago, Chile, ²⁴Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile, Santiago, Chile, ²⁵Universidad Simón Bolívar, Barranquilla, Colombia y Clínica de la Costa, Barranquilla, Colombia, ²⁶Clínica de la Costa y Universidad Simón Bolívar Barranquilla, Barranquilla, Colombia, Barranquilla, Colombia, ²⁷Fundación Valle del Lili, Universidad Icesi, Cali, Colombia, Cali, Colombia, ²⁸Facultad de Medicina, Universidad Nacional de Colombia; Hospital Universitario Fundación Santa Fe de Bogotá; Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, ²⁹Pontificia Universidad Javeriana de Cali, Cali, Colombia, Cali, Colombia, ³⁰Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador, Guayaquil, Ecuador, ³¹Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico, Mexico City, Mexico, ³²Hospital de Especialidades del Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico, Mexico City, Mexico, ³³Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ³⁴Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico, ³⁵Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, Guadalajara, Mexico, ³⁶Facultad de Medicina de la Universidad Autónoma de San Luis Potosí y Hospital Central "Dr. Ignacio Morones Prieto," San Luis Potosi, Mexico, San Luis Potosi, Mexico, ³⁷Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., MONTERREY, Mexico, ³⁸Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asuncion, Paraguay, ³⁹Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asunción, Paraguay, ⁴⁰Hospital Nacional Edgardo Rebagliati Martins-EsSalud, Lima, Peru, Lima, Peru, ⁴¹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, ⁴²Hospital Nacional Cayetano Heredia Universidad Peruana Cayetano Heredia, Lima, Peru, Jesús María, Peru, ⁴³Hospital Docente Padre Billini, Santo Domingo, Distrito Nacional, Dominican Republic, ⁴⁴Hospital de Clínicas, Facultad de Medicina, UDELAR, Montevideo, Uruguay, Montevideo, Uruguay, ⁴⁵Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ⁴⁶Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ⁴⁷Rollins School of Public Health, Emory University, Atlanta, Georgia, USA, Acworth, GA
Background/Purpose: The concept of disease modification (DM) has been recently introduced to improve the long-term care of patients (pts) with SLE. DM is defined as…
Abstract Number: 1428 • ACR Convergence 2025
Ankylosing Spondylitis Related Mortality Trends in USA from 1999-2020: Analysis of CDC Wonder Database
Sanjana Thimmannagari¹, Shiamak Cooper², Asim Khanfar¹ and Candrika Dini Khairani¹, ¹Rochester General Hospital, Rochester, NY, ²Rochester General Hospital, Irondequoit, NY
Background/Purpose: Ankylosing spondylitis is a significant cause of mortality and morbidity in the United States (US), with a prevalence of 0.2%–0.5%. However, trends in mortality…
Abstract Number: 1304 • ACR Convergence 2025
The role of PET/CT in evaluating rheumatologic conditions in children with fever of unknown origin – a multicenter study
Neta Berlak¹, Lydia Christodoulou², Gil Amarilyo³, Oded Scheuerman⁴, Irit Tirosh⁵, Eyal Kristal⁶, Ester Forer⁷, Amit Carmi⁸, Alon Kalter⁹ and Yoel Levinsky¹⁰, ¹Schneider children's medical center of Israel, Tel Aviv, Israel, ²Tel Hashomer, Periatric rheumatology unit, Tel Aviv, Israel, ³Schneider Children's Medical Center of Israel, Kibbutz Maggal, Israel, ⁴schneider children's meidcal center of Israel, Petah tikva, Israel, ⁵Tel Aviv universty, Ramat Gan, Israel, ⁶Soroka medical center Beer Sheva, Beer Sheva, Israel, ⁷Soroka medical center, Beer Sheva, Israel, ⁸Schneider children's meidcal center of Israel, Tel Aviv, Israel, ⁹Schneider children's medical center of ISrael, Petah Tikva, Israel, ¹⁰Schneider Children's Medical Cenetr of Israel, Tel Aviv University, JERUSALEM, Israel
Background/Purpose: Fever of Unknown Origin (FUO) is a relatively common clinical challenge that is frequently referred for evaluation by pediatric rheumatologists. In many cases, it…
Abstract Number: 1410 • ACR Convergence 2025
Examining the Interchangeability of Two Different Patient-Reported Global Assessment Measures in an Observational Axial Spondyloarthritis Cohort
Connor Vershel¹, Mark Hwang², John Reveille³, Seokhun Kim⁴, Matthew A. Brown⁵, Michael Weisman⁶, Mariko Ishimori⁶ and Michael Ward⁷, ¹Department of Internal Medicine, Division of Rheumatology, John P. and Katherine G. McGovern School of Medicine at the University of Texas Health Science Center at Houston, Houston, TX, ²UTHealth Houston, Houston, TX, ³Department of Medicine, University of Texas Medical Center, Houston, TX, ⁴UTHealth Houston, Houston, ⁵Genomics England, London, United Kingdom, ⁶Cedars-Sinai Medical Center, LOS ANGELES, CA, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD
Background/Purpose: In axial spondyloarthritis cohorts, patient reported outcomes are vital for tracking disease progression and response to therapy. However, many cohorts enrolled prior to the…
Abstract Number: 1499 • ACR Convergence 2025
Predictors of Proteinuria Flares in Biopsy Positive Lupus Nephritis
Michelle Petri¹, Andrea Fava², Daniel Goldman¹ and Laurence Magder³, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: Over 20% of lupus nephritis (LN) patients progress to end stage kidney disease. One of the most important predictors is renal flare.Methods: The analysis…
Abstract Number: 1514 • ACR Convergence 2025
Serum Antigenome Profiling Reveals Diagnostic Models for Systemic Lupus Erythematosus
Yan Wang¹, Lulu Cao², Mengze Xu³, Jian Lu³, Jing He¹, Fanlei Hu⁴ and Zhanguo Li⁵, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, Beijing, China (People's Republic), ²Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, Beijing, ³State Key Laboratory of Protein and Plant Gene Research, Center for Bioinformatics, School of Life Sciences, Peking University, Beijing, China., Beijing, Beijing, China (People's Republic), ⁴Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China (People's Republic), ⁵Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, Beijing, Beijing, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) exhibits profound clinical and pathogenic heterogeneity, complicating diagnosis and treatment. Identifying subtype-specific biomarkers might intrinsically link to organ involvement.Methods: Patients…
Abstract Number: 1464 • ACR Convergence 2025
Incidence of Major Adverse Cardiovascular Events (MACE) in Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis Patients With and Without Cardiovascular Risk Factors Treated With Secukinumab: Five-Year Safety Data from the Real-World SERENA Study
Uta Kiltz¹, Petros Sfikakis², Andreas Bounas³, Nicola Gullick⁴, Eric LESPESSAILLES⁵, Jan Brandt-Juergens⁶, Rasho Rashkov⁷, Cynthia Vizcaya⁸, Andreas Clemens⁸, Lara Gómez⁹, Kim Hoyt¹⁰, Weibin Bao¹¹ and Karl Gaffney¹², ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²NKUA - SCHOOL OF MEDICINE, Athens, Greece, ³‘OLYMPION’, General Clinic of Patra, Patra, Greece, ⁴Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK, Coventry, United Kingdom, ⁵University Hospital of Orléans, Orleans, France, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Clinic of Rheumatology, University Hospital St. Ivan Rilski, Sofia, Bulgaria, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Farmaceutica, Madrid, Spain, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹²Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom
Background/Purpose: Patients with psoriasis (PsO), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) are at increased risk of major adverse cardiovascular events (MACE) due to systemic…
Abstract Number: 1438 • ACR Convergence 2025
Similar Efficacy of Bimekizumab in Two Clinical Endotypes of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies and Their Open-Label Extension
Félicie Costantino¹, Ann-Sophie De Craemer², Filip Van den Bosch², Maxime Breban³, Vanessa Taieb⁴, Diana Voiniciuc⁵, Natasha de Peyrecave⁶, Dirk Elewaut⁷ and Maria-Antonietta D'Agostino⁸, ¹Department of Rheumatology, Ambroise Paré Hospital, AP-HP, Paris, France and Infection & Inflammation, UMR ¹¹⁷³, Inserm, UVSQ/Université Paris Saclay, Montigny-Le-Bretonneux, France, ²Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ³CHU Ambroise-Paré, Boulogne-Billancourt, France, ⁴UCB, Colombes, France, ⁵UCB, Slough, United Kingdom, ⁶UCB, Brussels, Belgium, ⁷VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, ⁸Department of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease mainly affecting the sacroiliac joints and spine.1 Peripheral manifestations are common, contributing to disease burden.2 Two…
Abstract Number: 1314 • ACR Convergence 2025
Protein-Specific Anti-Malondialdehyde-Acetaldehyde Antibodies and Cardiovascular Disease Outcomes in Rheumatoid Arthritis
Julia King¹, Michael Duryee¹, Punyasha Roul², Katherine Wysham³, Grant Cannon⁴, Gary Kunkel⁵, John Richards⁶, Isaac Smith⁷, Beth Wallace⁸, Gail Kerr⁹, Andreas Reimold¹⁰, Pascale Schwab¹¹, Daniel Anderson¹², Wenxian Zhou¹³, Joshua Baker¹⁴, Ted Mikuls¹, Bryant England¹ and Tate Johnson¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ⁷Duke University Hospital, Durham, NC, ⁸Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁹Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹⁰Dallas VA Medical Center, Dallas, TX, ¹¹VA Portland and Oregon Health & Science University, Portland, OR, ^120587964, Durham, NC, ¹³University of Nebraska Medical Center, Bellevue, NE, ¹⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cardiovascular disease (CVD) remains the leading cause of death in rheumatoid arthritis (RA), driven primarily by atherosclerotic CVD (ASCVD) and heart failure (HF). Malondialdehyde-acetaldehyde…
Abstract Number: 1413 • ACR Convergence 2025
Restless Legs Syndrome in Patients with Psoriatic Arthritis: Association with Inflammatory, Clinical Parameters, and Comorbidities
Esther Toledano¹, Carlos Villegas², Carolina Cristina Chacón³, Cristina Hidalgo Calleja³, Belén Miguel³, Laura Blanco³, Ana Turrión⁴, Olga Compán⁵, Manuel Martín⁴, Susana Gómez³ and Carlos Montilla³, ¹Rheumatology Service, San Carlos Clinical Hospital, Madrid, Spain, ²Faculty of Medicine, University of Salamanca, Salamanca, Spain, ³Rheumatology Service, University Hospital of Salamanca, Salamanca, Castilla y Leon, Spain, ⁴Rheumatology Service, University Hospital of Salamanca, Salamanca, Spain, ⁵Rheumatology Service, University Hospital of Salamanca, Carbajosa de la Sagrada, ³⁷¹⁹¹, Spain
Background/Purpose: Restless legs syndrome (RLS) is a chronic neurological disorder associated with brain iron metabolism. Although RLS has been linked to various immune-mediated inflammatory diseases,…
Abstract Number: 1056 • ACR Convergence 2025
High diagnostic rate of genetic testing in adult patients with autoinflammation: A Single Center Experience
Atif Towheed¹, Joshua Owens², Ann Parody¹ and Daniella Schwartz³, ¹University of Pittsburgh Medical Centre, Pittsburgh, ²UPMC Children’s Hospital of Pittsburgh, Pittsburgh, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Inborn errors of immunity (IEI), including autoinflammatory diseases and primary immune regulation disease (PIRD), are unfamiliar to many adult rheumatologists, leading to potential ascertainment…
Abstract Number: 1473 • ACR Convergence 2025
Comparison of Three Different Double-Stranded DNA Antibody Assays in the Diagnosis of Systemic Lupus Erythematosus
Anika Morgado¹, Sowmika Rao², Lili Tao¹ and Narender Annapureddy³, ¹Vanderbilt University Medical centre, Nashville, ²Vanderbilt University Medical Center, Nashville, ³Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Double-stranded DNA (dsDNA) antibodies are among the most specific biomarkers for systemic lupus erythematosus (SLE). They are associated with disease activity and are incorporated…
Abstract Number: 1518 • ACR Convergence 2025
Efficacy and Safety of Anifrolumab in Discoid Lupus: A Meta-Analysis of the Literature
Ali Ali¹, Neelay Purohit², Ciji Robinson², Amanda Darzi³ and Alireza Meysami⁴, ¹Department of Internal Medicine, Division of Rheumatology, Henry Ford Health System, Canton, MI, ²Department of Internal Medicine, Division of Rheumatology, Henry Ford Health System, Detroit, MI, ³Department of Internal Medicine, Henry Ford Health System, Detroit, MI, ⁴Henry Ford Health, Detroit, MI
Background/Purpose: Anifrolumab, a monoclonal antibody targeting the type I interferon receptor, demonstrated clinical efficacy in systemic lupus erythematosus in the pivotal TULIP-2 trial¹. However, its…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].